Efficacy and Safety of Trastuzumab Deruxtecan in the Treatment of HER2-Low/Positive Advanced Breast Cancer: A Single-Arm Meta-Analysis

This meta-analysis assessed the efficacy and safety of trastuzumab deruxtecan (DS-8201) in treating HER2-low/positive advanced breast cancer, involving 1,108 patients from 10 studies. The overall response rate (ORR) was 57%, with higher efficacy in HER2-positive patients (64% ORR) compared to those with low HER2 expression (46% ORR). The disease control rate (DCR) was 92%, with HER2-positive patients showing a higher DCR (96%) than those with low HER2 expression (87%). Common adverse events included nausea (62%), fatigue (44%), and hair loss (38%), with drug-related interstitial lung disease occurring in 10.5% of patients. Despite promising results, the study noted limitations such as small sample sizes and nonrandomized studies, highlighting the need for further research.